Reduced Post-transplant Cyclophosphamide Dose with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

Scientists compared the outcomes with a reduced Post-transplant cyclophosphamide (PT-Cy) total dose to those with the standard PT-Cy dose in haploidentical hematopoietic cell transplantation patients aged ≥ 65 years and those with cardiac comorbidities.